OSAIRIS: Lessons Learned From the Hospital-Based Implementation and Evaluation of an Open-Source Deep-Learning Model for Radiotherapy Image Segmentation.

Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published Date:

Abstract

Several studies report the benefits and accuracy of using autosegmentation for organ at risk (OAR) outlining in radiotherapy treatment planning. Typically, evaluations focus on accuracy metrics, and other parameters such as perceived utility and safety are routinely ignored. Here, we report our finding from the implementation and clinical evaluation of OSAIRIS, an open-source AI model for radiotherapy image segmentation that was carried out as part of its development into a medical device. The device contours OARs in the head and neck and male pelvis (referred to as the prostate model), and is designed to be used as a time-saving workflow device, alongside a clinician. Unlike standard evaluation processes, which heavily rely on accuracy metrics alone, our evaluation sought to demonstrate the tangible benefits, quantify utility and assess risk within a specific clinical workflow. We evaluated the time-saving benefit this device affords to clinicians, and how this time-saving might be linked to accuracy metrics, as well as the clinicians' assessment of the usability of the OSAIRIS contours in comparison to their colleagues' contours and those from other commercial AI contouring devices. Our safety evaluation focused on whether clinicians can notice and correct any errors should they be included in the output of the device. We found that OSAIRIS affords a significant time-saving of 36% (5.4 ± 2.1 minutes) when used for prostate contouring and 67% (30.3 ± 8.7 minutes) for head and neck contouring. Combining editing time data with accuracy metrics, we found the Hausdorff distance best correlated with editing-time, outperforming dice, the industry-standard, with a Spearman correlation coefficient of 0.70, and a Kendall coefficient of 0.52. Our safety and risk-mitigation exercise showed that anchoring bias is present when clinicians edit AI-generated contours, with the effect seemingly more pronounced for some structures over others. Most errors, however, were corrected by clinicians, with 72% of the head and neck errors 81% of the prostate errors removed in the editing step. Notably, our blinded clinician contour rating exercise showed that gold standard clinician contours are not rated more highly than the AI-generated contours. We conclude that evaluations of AI in a clinical setting must consider the clinical workflow in which the device will be used, and not rely on accuracy metrics alone, in order to reliably assess the benefits, utility and safety of the device. The effects of human-AI inter-operation must be evaluated to accurately assess the practical usability and potential uptake of the technology, as demonstrated in our blinded clinical utility review. The clinical risks posed by the use of the device must be studied and mitigated as far as possible, and our 'Mystery Shopping' experiment provides a template for future such assessments.

Authors

  • A D Constantinou
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Electronic address: adc76@cantab.ac.uk.
  • A Hoole
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • D C Wong
    Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.
  • G S Sagoo
    Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK.
  • J Alvarez-Valle
    Health Intelligence, Microsoft Research, Cambridge, UK.
  • K Takeda
    Graduate School of Integrated Science and Technology, Shizuoka University, Hamamatsu, Japan.
  • T Griffiths
    Clinical Engineering Innovation, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Computing, University of Dundee, UK.
  • A Edwards
    Clinical Engineering Innovation, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • A Robinson
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • L Stubbington
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • N Bolger
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Y Rimmer
    Oncology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • T Elumalai
    Oncology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • K T Jayaprakash
    Oncology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • R Benson
    Oncology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • I Gleeson
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • R Sen
    Oncology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • L Stockton
    Oncology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • T Wang
    Key Laboratory of National Health Commission on Parasitic Disease Control and Prevention, Jiangsu Provincial Key Laboratory on Parasite and Vector Control Technology, Jiangsu Institute of Parasitic Diseases, Public Health Research Center of Jiangnan University, Wuxi 214064, China.
  • S Brown
    Oncology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • E Gatfield
    Oncology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • C Sanghera
    Oncology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • A Mourounas
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • B Evans
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • A Anthony
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • R Hou
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • M Toomey
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • K Wildschut
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • A Grisby
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • G C Barnett
    Oncology Department, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • R McMullen
    Medical Physics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • R Jena
    Department of Oncology, University of Cambridge, Cambridge, UK. Electronic address: rjena@nhs.net.